Dianthus Therapeutics Financials - Benzinga

Dianthus Therapeutics Inc

DNTHNASDAQ

Trade with Public

Trade with Public

$104.77

-2.92-2.71%

At close: Sep 14, 5:00 PM EST

$104.55

-3.14-2.92%

Pre-Market: 4:10 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Dianthus Therapeutics Financials

Dianthus Therapeutics (DNTH) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Dianthus Therapeutics Q2 EPS $(0.90) Misses $(0.88) Estimate, Sales $761.000K Beat $258.583K Estimate

Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.88) by 2.27 percent. This is a 2.27 percent decrease over losses of $(0.88) per share

Benzinga Newsdesk

PRO
Dianthus Therapeutics Q1 EPS $(0.85) Beats $(1.07) Estimate, Sales $463.000K Beat $354.214K Estimate

Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate of $(1.07) by 20.56 percent. This is a 3.66 percent decrease over losses of $(0.82) per share

Benzinga Newsdesk

Dianthus Therapeutics Earnings Review: Q4 Summary

Benzinga Insights

PRO
Dianthus Therapeutics Q4 EPS $(1.43) Misses $(1.02) Estimate, Sales $284.000K Miss $398.917K Estimate

Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(1.43) per share which missed the analyst consensus estimate of $(1.02) by 39.51 percent. This is a 76.54 percent decrease over losses of $(0.81) per

Benzinga Newsdesk

PRO
Dianthus Therapeutics Q3 EPS $(0.97) Misses $(0.89) Estimate, Sales $396.000K Miss $576.400K Estimate

Benzinga Newsdesk

PRO
Dianthus Therapeutics Q2 EPS $(0.88) Misses $(0.86) Estimate, Sales $193.00K Miss $1.01M Estimate

Benzinga Newsdesk